APA (7th ed.) Citation

L, G., U, K., GE, V., M, G., MH, A., S, A., . . . CD, M. (2025). Bedaquiline, delamanid, linezolid, and clofazimine for rifampicin-resistant and fluoroquinolone-resistant tuberculosis (endTB-Q): An open-label, multicentre, stratified, non-inferiority, randomised, controlled, phase 3 trial. The Lancet. Respiratory medicine, 13(9), 809. https://doi.org/10.1016/S2213-2600(25)00194-8

Chicago Style (17th ed.) Citation

L, Guglielmetti, et al. "Bedaquiline, Delamanid, Linezolid, and Clofazimine for Rifampicin-resistant and Fluoroquinolone-resistant Tuberculosis (endTB-Q): An Open-label, Multicentre, Stratified, Non-inferiority, Randomised, Controlled, Phase 3 Trial." The Lancet. Respiratory Medicine 13, no. 9 (2025): 809. https://doi.org/10.1016/S2213-2600(25)00194-8.

MLA (9th ed.) Citation

L, Guglielmetti, et al. "Bedaquiline, Delamanid, Linezolid, and Clofazimine for Rifampicin-resistant and Fluoroquinolone-resistant Tuberculosis (endTB-Q): An Open-label, Multicentre, Stratified, Non-inferiority, Randomised, Controlled, Phase 3 Trial." The Lancet. Respiratory Medicine, vol. 13, no. 9, 2025, p. 809, https://doi.org/10.1016/S2213-2600(25)00194-8.